Your browser doesn't support javascript.
loading
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal, Michael; Karimi, Mohsen; Khan, Rasheed; Aggerholm, Anni; Antunovic, Petar; Astermark, Jan; Bernell, Per; Engström, Lena-Maria; Kjeldsen, Lars; Linder, Olle; Nilsson, Lars; Olsson, Anna; Holm, Mette S; Tangen, Jon M; Wallvik, Jonas; Oberg, Gunnar; Hokland, Peter; Jacobsen, Sten E; Porwit, Anna; Hellström-Lindberg, Eva.
Affiliation
  • Grövdal M; Division of Haematology, Department of Medicine, Centre for Experimental Haematology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. michael.grovdal@ki.se
Br J Haematol ; 150(3): 293-302, 2010 Aug.
Article in En | MEDLINE | ID: mdl-20497178
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Azacitidine / Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Antimetabolites, Antineoplastic Type of study: Etiology_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 2010 Type: Article Affiliation country: Sweden
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Azacitidine / Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Antimetabolites, Antineoplastic Type of study: Etiology_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 2010 Type: Article Affiliation country: Sweden